In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys.
The therapeutic efficacy of imidocarb, artesunate, arteether, buparvaquone and arteether+buparvaquone combination was evaluated against Babesia equi of Indian origin in splenectomised donkeys with experimentally induced acute infection. Efficacies of these drugs were tested by administering each drug or drug combination to groups of donkeys (having three donkeys each group). One group of donkey was kept as untreated control for comparing the results. Parasitaemia, haematology (WBC, RBC, PCV, granulocytes and haemoglobin), biochemical parameters (SAST, SALT, alkaline phosphatase, albumin/globulin ratio) were monitored at regular intervals. Individually, arteether and buparvaquone were found to have no parasite clearing efficacy and the treated animals died within 5-6 days after showing high parasitaemia and clinical symptoms of the disease. However, artesunate treated animals were able to restrict the parasite multiplication but only during the treatment period. Animals treated with imidocarb and arteether+buparvaquone combination were able to clear the parasite from the blood circulation after 2-5 days post-treatment (PT). After 55-58 days PT, recrudescence of B. equi parasite was observed in both these groups and a mean survival period of 66 days and 69 days, respectively, was recorded in these groups. Results of haemato-biochemical parameters had shown that imidocarb had deleterious effect on the liver function while on the other hand arteether+buparvaquone combination was found to be safe. This limited study indicates that arteether+buparvaquone combination could be a better choice than imidocarb for treating B. equi infection, but further trials are required in detail.
Kumar
Sanjay
S
National Research Centre on Equines, Haryana, India.
Gupta
Ashok K
AK
Pal
Yash
Y
Dwivedi
Shailendra K
SK
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use; D001404:Babesiosis / Q000188:drug therapy* / Q000662:veterinary*; D001772:Blood Cell Count / Q000662:veterinary; D004359:Drug Therapy, Combination; D018397:Equidae / Q000097:blood / Q000469:parasitology*; D007095:Imidocarb / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007194:India; D009285:Naphthoquinones / Q000008:administration & dosage / Q000627:therapeutic use; D012717:Sesquiterpenes / Q000008:administration & dosage / Q000627:therapeutic use; D013156:Splenectomy / Q000662:veterinary
D000981:Antiprotozoal Agents; D037621:Artemisinins; D009285:Naphthoquinones; D012717:Sesquiterpenes; C046326:buparvaquone; D007095:Imidocarb; C031327:artemisinin; C031719:imidocarb dipropionate